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AbstrACt
background Acute appendicitis is one of the most 
common acute surgical emergencies in children and 
accounts for an annual cost of approximately £50 million 
to the National Health Service. Investigating alternative 
treatment options offers the best prospect of enhancing 
the quality of care for patients and potential opportunities 
for cost savings through better allocative efficiency. A 
feasibility randomised controlled trial (RCT) comparing a 
non-operative treatment pathway with appendicectomy 
for children with acute uncomplicated appendicitis is 
underway (CONTRACT feasibility RCT).
Aims The prime objective of this economic substudy 
conducted alongside the CONTRACT feasibility RCT is to 
better understand and assess: (1) cost data collection tools 
and cost drivers by identifying patients’ pathways and (2) 
patient quality of life by assessing alternative paediatric 
health-related quality of life (HRQoL) instruments. 
Outcomes from this study will inform a future efficacy RCT 
assessing the effectiveness and cost-effectiveness of non-
operative treatment pathway for the treatment of acute 
uncomplicated appendicitis in children.
Methods The economic substudy will use individual-
level data and will be conducted from the health system 
perspective over the study’s 6-month follow-up period. 
Microcosting will include health resource and service 
use, while potential benefits acquired will be measured 
using the HRQoL measures, Child Health Utility 9D (CHU-
9D) and Euroqol-5 dimensions and 5 levels (EQ-5D-5L). 
We will assess the appropriateness of using the cost per 
quality-adjusted life year framework in the future RCT, as 
well as testing and identifying the most suitable HRQoL 
instrument.
Conclusions The outcomes of the investigational 
economic substudy will be used to inform the design of 
our future definitive RCT. However, the result from this 
economic study will also provide a detailed description 
and account of the issues inherent in paediatric Economic 
Evaluations Alongside Clinical Trials with an emphasis on 
costing methods of interventions taking place in secondary 
care settings.
trial registration number ISRCTN1583043.
IntroduCtIon
background
Acute appendicitis is one of the most 
common acute surgical emergencies in chil-
dren. According to the National Schedule 
of Reference Costs/Healthcare Resource 
Groups (HRG) data, almost 14 000 opera-
tions are performed every year in the UK 
(<18 years). Appendicectomy procedure for a 
patient under 18 years old costs on average 
from £3072 to £5992 and accounts for an 
annual total cost of approximately £50 million 
to the National Health Service (NHS).1 
For many years, appendicectomy has 
been considered the standard treatment for 
appendicitis, both in adults and in children. 
However, there is great current interest in 
the role of non-operative treatment (with 
antibiotics alone) of adults and children with 
acute appendicitis. Alongside evaluations of 
the clinical effectiveness of this alternative 
treatment option, it is equally important to 
explore the economic implications. A small 
number of studies have reported (mainly 
clinical) outcomes of non-operative treat-
ment of acute appendicitis in children, but 
very little is published on how this trans-
lates into economic outcomes.2–5 Therefore, 
the economic impact of different treatment 
options on the health system (eg, NHS) 
if adopted remains largely unknown. We 
plan to conduct a definitive randomised 
controlled trial (RCT) comparing these alter-
native treatment options. Since recruitment 
to such an RCT will be challenging, we are 
first conducting a feasibility RCT in the UK.6 
Alongside this feasibility RCT, we will conduct 
a health economic feasibility substudy to 
inform a future cost-effectiveness and cost–
utility analysis (CUA) within our definitive 
RCT. Herein, we describe the protocol for this 
health economic substudy. We aim to address 
the following research questions: what are 
the cost implications of treating childhood 
appendicitis non-operatively as compared 
with surgery; how the costs of both treatment 
options compare with widely used NHS Refer-
ence Costs; and what could be the implica-
tions of differing cost methods in assessing 
the cost-effectiveness of appendicitis. The 
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study will also assess two preference-based quality of life 
(QoL) questionnaires widely used in paediatric research, 
using as reference case, clinical outcomes identified 
through the feasibility study.
study design, participants, interventions and outcomes
The CONservative TReatment of Appendicitis in Chil-
dren – randomised controlled Trial (CONTRACT) 
study is a feasibility RCT that aims to explore whether 
it is feasible and acceptable to conduct a multicentre 
RCT testing the effectiveness and cost-effectiveness of a 
non-operative treatment pathway for the treatment of 
acute uncomplicated appendicitis in children. The study 
is being conducted in three specialist NHS Paediatric 
Units in England and participants are children (age 4–15 
years) with a clinical diagnosis of acute uncomplicated 
appendicitis. It has been estimated that 52–65 partici-
pants in the feasibility RCT will be adequate to test treat-
ment pathway procedures. The health technology under 
assessment involves treatment with antibiotics (intra-
venous followed by oral) and regular clinical review to 
determine disease resolution without appendicectomy 
or appendicectomy in those whom the disease worsens 
or fails to resolve. The broad inclusion criteria reflect 
current clinical practice and enable the generalisability 
of our results for routine inpatient care. The principal 
outcome of the feasibility study will be recruitment rate. 
A full protocol of the CONTRACT feasibility RCT is 
published elsewhere.6 
scope of the economic substudy protocol
The economic substudy will provide evidence and guid-
ance for determining data collection tools measuring 
cost and benefit outcomes for our future RCT assessing 
the cost-effectiveness of the non-operative treatment of 
appendicitis. Data management will be performed by 
the Southampton Clinical Trials Unit, and anonymised 
data will be delivered for the health economic anal-
ysis. This protocol describes methods for incorporating 
economic evidence into an early stage of the study and 
has been conceptually divided into two parts: (1) meas-
uring resource utilisation and conducting microcosting, 
and (2) measuring QoL and assessment of health-related 
QoL (HRQoL) instruments.
Methods And AnAlysIs
Part I: resource utilisation and costs
Costs are an important part of any economic evaluation 
but is a term that has different meaning across different 
disciplines. In Health Economics, costs are related to 
opportunity costs, and the question of interest is the 
choice between two alternatives; in other words, there are 
always forgone opportunities when choosing to invest in 
a new medical technology or health service rather than in 
a current treatment.7 8
Principles of costing within CONTRACT
The quality of the economic evaluation depends on the 
quality of the measurement of costs and outcomes.8–10 
There are two main approaches used to measure 
healthcare costs: the ‘macrocosting/top-down’ and the 
‘microcosting/bottom-up’ approach.8 11–14 The gross or 
macrocosting method is commonly used in cost analysis 
providing an overview of the effect of costs, but it has 
been argued that it is not appropriate in many cases for 
economic evaluation, because it provides limited accu-
racy and detail.8 14 In the UK, it is common practice to 
use the NHS Reference Costs/HRGs, which provides 
national tariffs as the unit costs for different services and 
procedures. These unit costs are calculated using the 
mean costs among patients and hospitals. However, these 
national tariffs might not represent good estimates of real 
costs especially for new interventions, and some reports 
show cost estimate discrepancies between macrocosting 
and microcosting, ranging between 9% and 66%.15 
Advocates of the macrocosting approach highlight the 
advantages of this method, namely generalisability, easy 
to use and less time-consuming. Microcosting reflects 
the individual patient costs by identifying and collecting 
the actual individual resources used and estimating the 
economic costs of resources used. However, despite the 
micro-costing approach being regarded as more accurate 
and transparent, it is considered time-consuming and not 
easily applied in some settings.14 A general rule recom-
mended by Beecham and Knapp16 is that the broader 
and most accurate approach is collecting individual data 
through a microcosting method or adopting a ‘reduced 
list costing’,17 which implies the selection of a limited 
number of services considered to be of most significance.
Detailed recommended methodology on costing is still 
lacking, but several guidelines have emerged13 18–21 such 
as a series of task force reports on methodological issues 
in costing methods by the International Society for Phar-
macoeconomics and Outcomes Research.20 22 However, 
guidelines still vary in terms of recommended methods, 
and variations of costing methods affect the validity and 
comparability of economic evaluation results.23 24 Our 
approach in this economic study is to compare the two 
methods in an attempt to minimise costing bias and 
improve choice of instruments that will be used in our 
future RCT.
Aims
 ► To develop and assess resource use data collection 
tools in support of the future economic evaluation 
within our definitive future RCT.
 ► To conduct microcosting of both treatment pathways 
and to explore what are the determinants of variation 
in costs across settings and methods (macrocosting vs 
microcosting).
 ► To provide an economic rationale for the use of the 
most appropriate resource use identification, valua-
tion and data collection tools.
 o
n
 26 Septem
ber 2018 by guest. Protected by copyright.
http://bmjpaedsopen.bmj.com/
bmjpo: first published as 10.1136/bmjpo-2018-000347 on 21 September 2018. Downloaded from 
3Chorozoglou M, et al. BMJ Paediatrics Open 2018;2:e000347. doi:10.1136/bmjpo-2018-000347
Open access
Identifying what costs are to be included
A microcosting approach to data identification and collec-
tion will be adopted. This approach will allow identifica-
tion of resource use, meaning it will be focused and able 
to provide rich data about the resources used in relation to 
managing paediatric acute appendicitis in secondary care. 
Each stage of the data collection refers to event pathways 
for activity costing so that context and information is not 
lost in the final outcome of each activity. The process will 
include identification of services, how the service works 
and which components of costs are incurred on delivery of 
each service. We will design and map processes involved in 
service delivery in order to identify all relevant resource use. 
Therefore, the details of the inpatient resource use will be 
collected through the design and implementation of case 
report forms that will be informed from hospital records 
(from which medical history and previous and concurrent 
medication will be summarised), clinical and office charts, 
laboratory and pharmacy records, diaries, microfiches, radi-
ographs and correspondence. Detailed analysis of patients’ 
hospital records will be undertaken for the first 10 patients 
recruited into CONTRACT across all three participating 
sites. This will enable an initial inclusive list of resource use 
items to be created and updated based on actual patient 
data using microcosting principles. This work will inform the 
resource use data collection tool that will be used to collect 
data for the remainder of the recruited patients. Addition-
ally, patient diary cards will be used to record resource use 
during the 14 days immediately following discharge from 
hospital. These will be used to collect data on use of anti-
biotics, pain medications and anti-inflammatory or other 
relevant medications, as well as productivity loss and absence 
from school information. Finally, a modified version of the 
Client Service Receipt Inventory (CSRI)16 25 questionnaire 
will be used to collect other resource use data. The CSRI is 
a research instrument developed in the mid-1980s to collect 
information on service utilisation, income, accommodation 
and other cost-related variables. This will include healthcare 
appointments and additional family-borne costs, as reported 
by parents of participants at 6 weeks following discharge and 
at 6 months.
Measuring and valuing resource use
Following identification of the patient’s pathway and the 
services used, we will design a comprehensive list of resource 
use items that will be included in our resource inventory 
collection tool. This approach will form a comprehen-
sive health profile of service utilisation that will form the 
outcome of this study and will lead to identification of the 
main cost drivers that need to be collected in our future 
definitive RCT. In this part of the study, we will use a mixed 
method approach for the valuation of the resources used. 
This valuation will use unit costs from both the Personal 
Social Services Research Unit and the NHS Reference Costs 
data. Additionally, as part of our microcosting approach, we 
will collect and compare unit cost data from participating 
hospitals.14
Data collection and analysis
After choosing the items of resource use to be included in 
this study, we will classify them in different components 
depending on the characteristics of the care pathway 
and service systems involved. Classifying resource use 
and costs implies focusing on variation at individual and 
aggregate level by trial arm. The economic substudy at 
this stage will allow us to verify the relevance of this vari-
ation.
Both datasets of resource use and costs, at individual 
and aggregate level, will allow us to identify the main 
factors that influence the cost of the intervention and will 
form the basis for considering the main cost drivers and 
methodology for inclusion in our definitive RCT. We will 
assess data quality and missing data identifying the most 
appropriate approach collecting economic data along-
side randomised clinical studies. Descriptive statistics will 
be performed to summarise data and problems identi-
fied will be discussed and presented in a relevant publi-
cation. External validation will be achieved by comparing 
the outcomes from our bottom-up microcosting to the 
NHS Reference Costs, and the HRG tariff to identify 
the most appropriate costing method. We envisage that 
in case of significant variation in the costing methods, 
we will be able to adopt both methods in our future 
cost-effectiveness analysis (CEA) in the form of sensitivity 
analysis. Given the importance of costs in any CEA, this 
proposed work will allow defining uncertainty around 
the CEA results and will provide an evidence base for 
future research.
Part II: preference-based hrQol instruments and the quality-
adjusted life year (QAly) framework
The most commonly cited and used paediatric prefer-
ence-based generic HRQoL instruments are the Health 
Utility Index (HUI),26 Euroqol 5 dimensions youth 
version (EQ-5D-Y)27 and CHU-9D.28 In the UK, there is a 
tendency towards the use of the EQ-5D-Y due to recom-
mendation by NICE for adult population (EQ-5D-3L29 30). 
The EQ-5D-Y comprises the same 3 L as the adult version 
with improved wording for children despite not having a 
child specific value set. Euroqol states that ‘Recent research 
has indicated that regular EQ-5D-3L value sets cannot be used 
for children and adolescents. The main reason is that health 
states are valued differently when described for an adult or a 
child.’.
More recently, a relatively new paediatric instrument, 
CHU-9D, has become more widely used in the UK. This 
is the only preference-based HRQoL measure specifically 
designed and developed with children using UK general 
population value sets. The HUI, although a paediatric 
instrument, was initially developed for patients with 
cancer and is not used as much in the UK. We believe 
this is due to two reasons: first, it relies on preference 
values obtained from the Canadian general population 
and not a UK population, which might introduce some 
differences. Second, there is a cost attached to the use 
of HUI, and this could be an issue for consideration 
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when research studies need to operate under reasonably 
limited budget.
Principles of HRQoL assessment within CONTRACT
To enable detection of any effect of our intervention on 
HRQoL, we will collect data using two preference-based 
quality of life measures. The proposed measures are: (1) 
the EQ-5D-5L,31 which comprises the same five dimen-
sions as the EQ-5D-3L and EQ-5D-Y but five levels of 
severity, which is considered to significantly increase 
reliability and sensitivity (discriminatory power)31 32 
and (2) the CHU-9D, the paediatric generic quality of 
life measure specifically designed for use in studies with 
children, which comprises nine dimensions.28 33–36 Both 
measures will be obtained from parent/carer proxy 
responses and children if 7 years or older.
Aims
1. To compare two alternative preference-based gener-
ic HRQoL measures commonly used in paediatric 
studies.
2. To identify the most appropriate HRQoL instrument 
for economic evaluations alongside clinical studies for 
children with acute uncomplicated appendicitis in ter-
tiary care settings.
3. To assess the variation and impact of time of data 
collection on utility values and the QALY framework 
when used in this population.
Data collection and analysis
We will collect both HRQoL measures at baseline, 
discharge, 2 weeks (to determine any short-term differ-
ence in QoL that may not be apparent at later follow-up), 
6 weeks, 3 months and 6 months to define the most 
appropriate timing of assessment in relation to other 
health outcomes. Evidence from this work will support 
the decision for the most appropriate HRQoL instru-
ment to be used but also will provide valuable informa-
tion adopting and reporting results in our future CUA in 
terms of cost per QALY gained. Any imbalances detected 
will inform sensitivity analyses and, therefore, will enrich 
the results from the future definitive trial. We will also 
assess the appropriateness of using the QALY framework 
in this population, in terms of identifying aspects that are 
excluded from the conventional QALY framework, and 
aspects that the QALY framework could be sensitive in 
regards to timing of data collection.
ConCludIng reMArks
Costs of different interventions are an important part 
of any economic evaluation to determine whether a 
particular intervention is better placed, in terms of the 
outcomes it generates, in comparison with standard 
care.7 8 The two most commonly used methods of 
collecting cost data are either ‘macro/top-down’ or 
‘micro/bottom-up’ costing. The macrocosting uses the 
total budget to produce average costs per patient. This 
method is quicker but assumes that all patients have the 
same diagnosis, severity and treatment. Microcosting 
measures resource use by individual patient and there-
fore is considered more accurate detecting cost variability 
among patients. This method produces better quality 
costs but can be time-consuming and expensive.14 In this 
study, we will assess two HRQoL measures and the impli-
cations of adopting the QALY framework in our future 
economic evaluation. Incorporating the outcomes from 
this economic substudy into the feasibility stage of our 
RCT, and the microcosting method we adopt in doing 
so, we believe it will enhance our results and their appli-
cability for healthcare decision making and for future 
economic evaluations.
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